Skip to content
OpenCapital
Get started

OS Therapies OSTX Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price at other companies

CTO
Citius Oncology, Inc.CTOR
$0.80—

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice.

The official record: OS Therapies’s 10-Q, filed November 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's share based compensation arrangement by share based payment award fair value assumptions exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's share based compensation arrangement by share based payment award fair value assumptions exercise price?
OS Therapies (OSTX) reported share based compensation arrangement by share based payment award fair value assumptions exercise price of $1.12 in Q2 2025.
What does share based compensation arrangement by share based payment award fair value assumptions exercise price mean?
This metric represents the estimated fair value of equity-based awards granted to employees and directors, calculated using valuation models like Black-Scholes. It reflects the non-cash cost of compensation arrangements and provides insight into the company's strategy for talent retention and alignment with shareholder interests. Investors use this to assess the potential dilution impact and the underlying expense associated with equity incentive plans.